Health Trials

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

ConditionsClear Cell Renal Cell Cancer (ccRCC)Urothelial Carcinoma (UC)Colorectal CancerCervical CancerOvarian CancerHead and Neck CancerHepatocellular Carcinoma (HCC)CholangiocarcinomaNon Small Cell Lung CancerSmall Cell Lung CancerBreast CancerPancreatic CancerEndometrial CancerVon Hippel Lindau Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University First Hospital

About this trial

The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.

Eligibility criteria

Qualifiers

Written and voluntarily given Informed Consent.

Male or female ≥18 years of age at time of consent.

Have the capacity to understand the study and be willing and able to comply with all protocol requirements.

Disqualifiers

Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator.

Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study.

Be a female who is pregnant or breastfeeding.

Trial design

Treatments tested in this trial

  • 18F-T2 PET/CT

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Peking University First Hospital

Lead sponsor

Source ClinicalTrials.gov